Shares of Check Cap Ltd (NASDAQ:CHEK) have received an average broker rating score of 1.00 (Strong Buy) from the three brokers that cover the stock, Zacks Investment Research reports. Three investment analysts have rated the stock with a strong buy rating.
Brokerages have set a 12 month consensus target price of $52.52 for the company and are forecasting that the company will post ($1.68) EPS for the current quarter, according to Zacks. Zacks has also assigned Check Cap an industry rank of 183 out of 265 based on the ratings given to its competitors.
A number of brokerages have issued reports on CHEK. HC Wainwright began coverage on Check Cap in a research report on Tuesday, March 13th. They issued a “buy” rating and a $6.00 target price on the stock. Zacks Investment Research lowered Check Cap from a “buy” rating to a “hold” rating in a research report on Thursday, February 22nd. Finally, ValuEngine raised Check Cap from a “sell” rating to a “hold” rating in a research report on Wednesday.
An institutional investor recently bought a new position in Check Cap stock. Anson Funds Management LP purchased a new stake in Check Cap Ltd (NASDAQ:CHEK) in the fourth quarter, according to its most recent filing with the SEC. The fund purchased 332,302 shares of the medical research company’s stock, valued at approximately $289,000. Anson Funds Management LP owned about 1.73% of Check Cap at the end of the most recent quarter. Hedge funds and other institutional investors own 22.18% of the company’s stock.
Shares of NASDAQ CHEK traded down $0.61 during midday trading on Friday, hitting $3.59. The stock had a trading volume of 29,722 shares, compared to its average volume of 27,877. Check Cap has a 1-year low of $3.58 and a 1-year high of $27.60.
Check Cap (NASDAQ:CHEK) last released its quarterly earnings results on Wednesday, April 4th. The medical research company reported ($1.22) EPS for the quarter, missing the consensus estimate of ($0.15) by ($1.07). sell-side analysts expect that Check Cap will post -6.48 EPS for the current fiscal year.
TRADEMARK VIOLATION WARNING: This piece of content was originally posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this piece of content on another website, it was copied illegally and republished in violation of international copyright and trademark legislation. The original version of this piece of content can be accessed at https://www.dispatchtribunal.com/2018/04/07/zacks-check-cap-ltd-chek-receives-average-recommendation-of-strong-buy-from-analysts.html.
Check Cap Company Profile
Check-Cap Ltd. (Check-Cap) is a clinical-stage medical diagnostics company. The Company is engaged in the development of an ingestible imaging capsule that utilizes low-dose X-rays for the detection and imaging of colonic polyps and colorectal cancers, or CRC. The Company’s system consists of main components, such as ingestible scanning capsule; Capsule Positioning System (CPS), a recorder worn on the patient’s back, and a personal computer (PC)-based work station for data reconstruction and image processing.
Get a free copy of the Zacks research report on Check Cap (CHEK)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Check Cap Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Check Cap and related companies with MarketBeat.com's FREE daily email newsletter.